Kidney Week 2026

ASN President's Medal, ASN President's Address, State-of-the-Art Lecture, Featured High-Impact Clinical Trials. Titles and authors of the late-breaking abstracts: https://www.asn-online.org/education/kidneyweek/2026/KW26_LBAs_PLEN1X.pdf Abstracts in this session will have corresponding poster presentations on the same day in the Exhibit Hall. Full abstracts will be available on the ASN website on October 22 and on the JASN website on November 10. Continuing education credits are not being offered for this session. Support is provided by Vertex Pharmaceuticals.

70 active late-breaking research posters. TH-PO1267 is withdrawn. Full abstracts will be posted on the ASN website on October 22 and on the JASN website on November 10. Continuing education credits are not offered for this session. Official titles and authors: https://www.asn-online.org/education/kidneyweek/2026/KW26_LBAs_LB-POX.pdf

The field of kidney transplantation spans all aspects of nephrology care, from advances in pathology and immunology to AKI and CKD management to health care delivery and policy. Experts in the field present the most important advances in kidney transplantation, as reflected in recent publications, and offer the opportunity to vote for the "Best in Show."

The search for accurate biomarkers in CKD is challenging. Disease modifiers may interfere in an already complex landscape. This session focuses on factors that could improve the evaluation of disease outcomes and conditions that affect cardiovascular disease, mineral metabolism, and CKD risk. Particular attention is given to CKD stage, age, and sex in humans and animal models.

The FIT Bowl will take place in the Futures Theater in the Exhibit Hall.

Obesity and CKD are interrelated. With the rapid uptake of GLP-1 receptor agonists (RAs), used alone or in combination with other therapeutic approaches, for the management of patients with obesity and CKD, clinicians face practical issues related to safety, treatment combinations, complications, and discontinuation of therapy. This session updates medical knowledge and informs clinical practice on the use of GLP-1 RAs and other approaches in the management of obesity in patients with CKD.

As the population of patients living with cancer continues to grow and survive longer, kidney diseases in oncology have become increasingly common, complex, and clinically significant. This clinical practice session provides a case-based, evidence-driven update on key challenges at the intersection of nephrology and oncology, with an emphasis on practical, frontline management strategies.

The cell cytoskeleton does more than provide a cellular scaffold in dynamic environments. This session examines how modulators of the cell cytoskeleton and mechanosensors can facilitate regeneration or promote further injury, thereby contributing to CKD progression after cellular stressors. Cutting-edge research is presented that elucidates how the cytoskeleton can uniquely alter mitochondrial function and affect proteinuria-mediated tubular injury, as well as the roles of podocyte mechanosensors and novel models of biomechanical forces in defining responses to kidney injury.

With the rapidly changing management landscape for glomerular diseases, this session reviews current challenges in diagnosis, prognostication, and treatment, with a particular focus on the roles of genetic testing and kidney biopsy in diagnosis and their potential future role in treatment selection. Future advances in risk stratification and prognostication are reviewed, as is the need for measures to assess the effects of living with a glomerular disease beyond eGFR and proteinuria.

Robust clinical trial evidence to guide treatments for preventing kidney stone diseases and pathological vascular calcification has been relatively sparse. Several important studies have helped fill this gap in recent years. This session describes a large, randomized study of kidney stones, groundbreaking treatments for primary hyperoxaluria type 1, and rigorous studies assessing the effects of vitamin K on vascular calcification and treatments for hyperphosphatemia in CKD progression.

This session presents current and emerging issues that patients face. Patients and medical and research professionals describe working together to implement current and new initiatives and to recommend greater patient involvement in research, policies, and procedures. The panel examines methods to find common ground to advance outcomes in innovative care, empower patients through education and involvement, and address ethical and economic issues that challenge US and global kidney communities.

Kidney biopsy is required to diagnose most glomerular diseases. However, a kidney biopsy may not be required to diagnose PLA2R-associated membranous nephropathy. The role of protocol and repeat kidney biopsies in IgAN, lupus nephritis, and ANCA-associated vasculitis is also controversial. The session addresses the role of repeat and protocol kidney biopsies in these diseases and the clinical and laboratory markers that can help guide the decision to biopsy or not to biopsy.

There is a shortage of nephrology providers and declining interest in nephrology fellowship programs. This session addresses nephrology workforce concerns and explores strategies to promote recruitment into nephrology, the role of advanced practice providers (APPs) in nephrology, and the pediatric nephrology workforce.

Recently, the FIND-CKD trial demonstrated the efficacy of a nonsteroidal mineralocorticoid antagonist in slowing eGFR decline among adults with CKD who do not have diabetes. This session presents additional analyses from this trial and other related studies that seek to define the scope and impact of this emerging treatment option in CKD. Note: Continuing education credits are not being offered for this session.

Advances in research are yielding innovative therapies for both rare and common kidney diseases at an unprecedented pace. But true progress is measured by patient access and use, not just approval. This session examines the complex barriers to the broad distribution of newly approved therapies for glomerular diseases, including expansion to pediatric patients, global availability, insurance approval, and real-world evidence on efficacy and adverse effects.

Hemoadsorption is an emerging extracorporeal therapy that removes inflammatory mediators, endotoxins, and select circulating compounds from critically ill patients. This session reviews the mechanisms of hemoadsorption and critically examines clinical evidence for its use in cardiac surgery-associated AKI, endotoxic septic shock, and maintenance hemodialysis. Experts also address considerations for drug removal and practical issues in patient selection, timing, and integration into extracorporeal circuits.

Oral Abstract Session